These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection. Barnes D; Talenti D; Cammell G; Goormastic M; Farquhar L; Henderson M; Vogt D; Mayes J; Westveer MK; Carey W Hepatology; 1997 Oct; 26(4):853-7. PubMed ID: 9328304 [TBL] [Abstract][Full Text] [Related]
4. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Trouillot TE; Shrestha R; Kam I; Wachs M; Everson GT Liver Transpl Surg; 1999 Sep; 5(5):375-80. PubMed ID: 10477838 [TBL] [Abstract][Full Text] [Related]
5. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499 [TBL] [Abstract][Full Text] [Related]
6. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study. Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment with ursodeoxycholic acid may reduce the incidence of acute cardiac allograft rejection. Bährle S; Szabó G; Stiehl A; Theilmann L; Dengler TJ; Zimmermann R; Kübler W J Heart Lung Transplant; 1998 Jun; 17(6):592-8. PubMed ID: 9662095 [TBL] [Abstract][Full Text] [Related]
8. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091 [TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation. Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324 [TBL] [Abstract][Full Text] [Related]
10. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients. Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237 [TBL] [Abstract][Full Text] [Related]
11. A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. Assy N; Adams PC; Myers P; Simon V; Ghent CN Gut; 2007 Feb; 56(2):304-6. PubMed ID: 17303606 [No Abstract] [Full Text] [Related]
12. Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation: a single-center experience. Toyoki Y; Hakamada K; Narumi S; Totsuka E; Nara M; Ono H; Ishizawa Y; Sasaki M Transplant Proc; 2004 Oct; 36(8):2279-81. PubMed ID: 15561218 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of immunosuppression withdrawal after liver transplantation. Girlanda R; Rela M; Williams R; O'Grady JG; Heaton ND Transplant Proc; 2005 May; 37(4):1708-9. PubMed ID: 15919439 [TBL] [Abstract][Full Text] [Related]
14. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. Tisone G; Orlando G; Cardillo A; Palmieri G; Manzia TM; Baiocchi L; Lionetti R; Anselmo A; Toti L; Angelico M J Hepatol; 2006 Apr; 44(4):702-9. PubMed ID: 16473433 [TBL] [Abstract][Full Text] [Related]
15. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616 [TBL] [Abstract][Full Text] [Related]
16. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Jorgensen R; Angulo P; Dickson ER; Lindor KD Am J Gastroenterol; 2002 Oct; 97(10):2647-50. PubMed ID: 12385454 [TBL] [Abstract][Full Text] [Related]
17. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Jacob DA; Neumann UP; Bahra M; Klupp J; Puhl G; Neuhaus R; Langrehr JM Clin Transplant; 2006; 20(2):211-20. PubMed ID: 16640529 [TBL] [Abstract][Full Text] [Related]
19. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A; Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245 [TBL] [Abstract][Full Text] [Related]
20. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]